🔗 Share this article

As America continues making sweeping revisions to its vaccination schedules, an unexpected name has surfaced somewhat surprisingly: Tracy Beth Høeg, a Danish American sports physician and epidemiologist who first made her name by casting doubt on COVID-19 shots in the global health crisis and has zeroed in on alleged fatalities following Covid immunization in her brief time at the Food and Drug Administration.

Proposed Overhauls to Pediatric Immunization Program

Agency leaders were set to unveil radical changes to the childhood vaccination calendar earlier this month, synchronizing the US with the Danish vaccine program, sources say – a substantial departure that would place the US out of step with much of the international standard with no evidence for benefit. The announcement has been delayed until the new year.

In place of the director of the vaccine center, Dr. Høeg is set to address the audience at the meeting. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the division this calendar year.

A Shift at the Regulatory Body

This interim role might represent a closer partnership between the drug and biologics divisions as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon dismantling already-approved vaccines at the FDA.

The new acting director has frequently advocated for ending specific childhood immunization guidelines in the US to become more similar to Denmark's approach, a country with comprehensive healthcare and a citizenry approximately the population of the state of Wisconsin.

To date comments, she has kept her attention on vaccination policy – typically the responsibility of Dr. Prasad, head of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Doubts Over Background

Dr. Høeg has no apparent experience in medication creation, regulation or leadership, which has been customary for former heads of the biologics center. She has worked at the FDA as a top consultant to the FDA chief and CBER since March.

“It seems she lacks to have the requisite experience” for leading the drug-regulation department, remarked Jonathan Howard. “She’s never run a scientific study. She lacks experience in leading a sizeable institution. She lacks background in drug approvals.”

Former heads of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of medication creation”, commented Janet Woodcock. “Clearly, she has not acquired the type of experience that prior appointees who headed CBER have had.”

The drug center has an vast workload at the FDA, she pointed out.

“Many people just focuses on the novel medication approvals, but the generic drug division clears thousands of generic medications. There is also a biologic copycat branch, over-the-counter program and other areas, and every single one must be managed,” Dr. Woodcock said. “The area you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Additionally, a major management aspect to the job, which oversees in excess of 5,000 personnel. “It’s a huge administrative position, if you execute it properly,” she said.

Official Statement and Controversial Initiatives

In response to concerns about Dr. Høeg's fitness for the role and whether this assignment represents increased cooperation among agency officials on immunizations, a representative responded that the “concerns are based on inaccurate premises”.

“Her experience is consistent with the responsibilities of her position,” the official stated, citing the months Dr. Høeg spent advising the agency head on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the agency head's new priority voucher program, a disputed one-day drug-approval program that allegedly troubled her former heads. “By what process are these drugs being chosen for this fast-track system? Who is making the choices?” Howard asked. “There is a lot of secrecy going on at the regulatory body right now.”

Broadly speaking, he said, “the agency looks to be trending towards more relaxed oversight of most medications, with the exception of immunizations.”

Established Past Work on Vaccines

Concerning immunizations, Høeg has a more established, if problematic, history, critics have noted. She authored a study using unverified volunteer-provided data to assess the rate of myocarditis after COVID-19 vaccination. She consulted for the Florida top health official Dr. Joseph Ladapo, who reportedly have modified findings to imply Covid vaccinations are riskier than they are.

Included in her “wish list” for the current government featured altering guidelines for recently developed shots and ending “non-essential” immunizations, she stated after the election on a audio program. At the agency, Høeg has allegedly floated the idea of preventing teenage boys from getting COVID-19 vaccinations.

“She’s an complete dogmatist who starts off with her conclusions and reverse-engineers to fit the science in a very disingenuous, dishonest way,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of other dissenters, {like|